GleamWall
中文EN

ETON Eton Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1710340 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY100.6%
TTM net income YoY846.2%
TTM EPS YoY703.3%
Revenue 3-yr CAGR62.6%
Net income 3-yr CAGR181.6%

Margins

Gross margin69.2%
Operating margin28.8%
Net margin35.3%
FCF margin27.1%
EBITDA margin31.4%

Returns

ROE90.6%
ROA38.1%
ROIC (approx.)115.0%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets44.7%
Debt / equity0.27x
Current ratio1.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio8.8%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$57.92M$37.59M$24.27M$21.28M$22.46M$18.93M$17.28M$11.65M
Cost of revenue$13.62M$12.18M$9.53M$8.18M$14.60M$7.00M$7.42M$5.17M
Gross profit$44.30M$25.41M$14.73M$13.10M$7.86M$11.92M$9.86M$6.48M
R&D expense$5.27M$993,000$1.88M$1.78M$1.11M$3.71M$1.16M-$871,000
SG&A expense$16.02M$11.63M$10.45M$8.86M$8.11M$9.69M$9.17M$6.72M
Operating income$23.01M$12.79M$2.41M$2.46M-$1.36M-$1.48M-$470,000$629,000
Interest expense—$1.01M$1.14M$1.21M$1.21M$1.20M$1.16M$1.33M
Pretax income$22.36M$11.72M$1.57M$1.41M-$1.96M-$2.52M-$1.50M-$511,000
Income tax-$12.89M$140,000$20,000-$69,000-$28,000$66,000$74,000$87,000
Net income$35.25M$11.58M$1.55M$1.48M-$1.93M-$2.58M-$1.57M-$598,000
EBITDA$23.03M$14.18M$3.54M$3.48M-$1.35M-$470,000$543,000$984,000
EPS (basic)1.230.420.06—-0.07-0.10-0.06—
EPS (diluted)1.060.350.05—-0.07-0.10-0.06—
Weighted avg. shares (diluted)33.26M32.79M31.55M—26.89M26.89M26.89M—
Balance sheet
Cash & equivalents$55.63M$26.84M$19.66M$25.94M$37.12M$25.38M$17.42M$14.94M
Receivables$26.43M$24.89M$13.41M$11.76M$13.08M$14.45M$16.40M$5.36M
Inventory$11.08M$10.14M$14.47M$15.42M$16.86M$23.79M$13.62M$15.23M
Current assets$96.78M$68.60M$53.24M$60.58M$72.00M$68.44M$49.96M$41.02M
PP&E, net$338,000$352,000$372,000$326,000$294,000$18,000$22,000$34,000
Intangibles$44.28M$45.68M$43.74M$30.88M$31.88M$32.88M$33.88M$34.88M
Total assets$157.27M$115.81M$97.71M$92.11M$104.51M$101.68M$84.03M$76.12M
Current liabilities$54.09M$45.12M$44.18M$38.49M$44.18M$38.60M$25.35M$19.95M
Short-term debt$11.84M$8.82M$11.81M$8.79M$2.78M$2.77M—$0
Long-term debt$11.23M$19.08M$18.94M$21.77M$27.59M$27.41M$29.99M$29.81M
Total debt$23.07M$27.90M$30.75M$30.56M$30.37M$30.18M$29.99M$29.81M
Total liabilities$70.35M$69.22M$67.09M$65.96M$81.38M$77.72M$59.58M$51.70M
Shareholders' equity$86.92M$46.59M$30.61M$26.15M$23.13M$23.96M$24.45M$24.43M
Net debt-$32.56M$1.06M$11.09M$4.62M-$6.75M$4.80M$12.57M$14.88M
Shares outstanding28.83M28.29M27.36M27.05M26.82M26.82M26.82M26.71M
Cash flow statement
Operating cash flow$35.24M$7.25M$7.41M-$11.55M$12.03M$7.96M$2.09M-$765,000
Capital expenditure$13,000-$5,000$75,000$49,000$284,000$0$0$12,000
Free cash flow$35.23M$7.26M$7.33M-$11.60M$11.74M$7.96M$2.09M-$777,000
Investing cash flow-$3.24M$5,000-$15.07M-$49,000-$284,000$0$0-$38.13M
Financing cash flow-$3.22M-$76,000$1.39M$421,000$0$0$394,000$33.57M
Depreciation & amortization$21,000$1.39M$1.13M$1.02M$8,000$1.00M$1.01M$355,000
Stock-based compensation$3.31M$1.47M$1.52M$1.12M$1.09M$2.10M$1.20M$782,000

Free plan shows the latest 8 periods; Pro shows all 36 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.